Knight Therapeutics (TSE:GUD) Reaches New 12-Month High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD) shares reached a new 52-week high on Monday . The company traded as high as C$9.74 and last traded at C$9.74, with a volume of 23150 shares traded. The stock had previously closed at C$9.45.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group set a C$9.50 price objective on shares of Knight Therapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of C$9.50.

Knight Therapeutics Price Performance

The firm has a market cap of C$949.39 million, a price-to-earnings ratio of 161.17, a P/E/G ratio of -1,013.50 and a beta of -0.14. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The stock’s fifty day moving average price is C$8.43 and its 200-day moving average price is C$7.06.

Knight Therapeutics (TSE:GUD) last issued its quarterly earnings data on Thursday, May 7th. The company reported C$0.13 earnings per share for the quarter. The company had revenue of C$147.59 million during the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. As a group, equities research analysts forecast that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current fiscal year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.